A Phase II, Multi-Center, Two-Tier Study of IMC-A12 in Combination with Depot Octreotide in Patients with Metastatic, Well- or Moderately-Differentiated Carcinoid or Islet Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2016
At a glance
- Drugs Cixutumumab (Primary) ; Octreotide
- Indications Carcinoid tumour; Neuroendocrine carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 12 Aug 2016 Status changed from active, no longer recruiting to completed.
- 01 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016.